Radium-223 (Ra-223) has been approved since 2013 for men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Since then, the treatment landscape has changed dramatically ...

Murilo De Almeida Luz, MD, discusses data on PSA and ALP changes in patients receiving enzalutamide plus radium-223 vs enzalutamide alone.

Radium-223, an alpha-emitting radionuclide, is the first agent of its kind approved for the treatment of mCRPC. Although a pivotal phase 3 study evaluated its short-term safety, 1 there is a need to ...

In this tutorial, I demonstrate a fall Aqua smokey eye paired with flawless skin. This new skin routine leaves me feeling and looking smooth all day. It's a great way to wear color without feeling ...

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

Just over three years ago, Bayer was forced to concede that its blockbuster expectations for Xofigo (radium Ra 223 dichloride) would come to nothing, after the castration-resistant prostate cancer ...

Boston-based biotech Ratio Therapeutics has doubled its funding at a stroke with a $20 million Series A that will be used to usher its targeted radiotherapies into clinical testing. The latest ...

She observed that the decay of the active deposit of radium and actinium depended in a marked way on the time of exposure to the respective emanations and determined the curve of decay for very ...

An expert discusses recent trial data showing that combining radium-223 with enzalutamide modestly improves outcomes in metastatic castration-resistant prostate cancer (mCRPC) with bone ...

The Total Value Locked (TVL) in DeFi protocols have crossed the biggest range in history as it is trading at its highest value of $223 billion.